T2D

2

Review clinical trials related to T2D. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Potatoes, Type 2 Diabetes, and Cardiometabolic Health

Type 2 diabetes (T2D) is a major chronic health condition which increases risk of coronary artery disease, frailty, cognitive decline, and mortality. Additionally, hypertension is a major comorbidity for individuals with T2D, further increasing the risk of adverse cardiovascular outcomes. The prevalence of both conditions increases with advancing age. There is an urgent need to identify new approaches to prevent the development of T2D and improve cardiometabolic health in older adults 50-70 years of age. Whole white potatoes are an unprocessed food rich in essential nutrients often under-consumed by Americans, including potassium, fiber, magnesium, vitamins C and B6, and phytochemicals. Each of these nutrients individually are associated with cardiometabolic health benefits. Potatoes account for a significant amount of the intake of these nutrients in the US diet and are well-positioned to be a foundational element of a healthy dietary pattern. However, there are few interventional studies evaluating the effect of potatoes on cardiometabolic health, and the evidence from observational studies is mixed, leaving a significant gap in knowledge regarding the potential for potatoes to be included in healthy dietary patterns. The results of our proposed study will provide foundational data that inform future dietary guidelines regarding the inclusion of white potatoes as part of a healthy US dietary pattern.

Participants needed: 42
Trial details
Age: 50-70Biological sex: AllType: InterventionalSponsor: Virginia Polytechnic Institute and State UniversityUpdated: Aug 4, 2026Locations: 1
Eligibility criteria

Age 50-70 years [+7]

Body mass index >40 m2/kg [+11]

Status: Not yet recruiting

Bioequivalence Study of GZR4 Injection With Different Manufacturing Processes in Healthy Adult Participants

This study is a single-center, open-label, randomized, single-dose bioequivalence trial conducted in healthy adult participants.

Participants needed: 64
Trial details
Phase: Phase 1Age: 18-50Biological sex: MaleType: InterventionalSponsor: Gan & Lee Pharmaceuticals.Updated: Jun 26, 2026Locations: 1
Eligibility criteria

1. Voluntarily sign the Informed Consent Form (ICF), be willing to accept subcut...

1. Have an allergic constitution, or a history of allergic diseases such as bron...